Search
Close this search box.

Blog

New Treatment Option Moving Towards Reimbursement for Adults with Operable Early-Stage NSCLC

Pembrolizumab (Keytruda) is one step closer to being funded via Canada’s various provincial drug plans for the treatment of adults with operable stage II, IIIA, or IIIB (T3 to 4N2) non-small cell lung cancer (NSCLC) to be used with chemotherapy before surgery to shrink the cancer and then used on its own after surgery to help keep the cancer from coming back, if certain conditions are met.

A Landmark Win, But More Work to Be Done 

Everyone Deserves to Breathe Easy. We need to speak up so Canadians across the country can get the help they need close to home. Thanks to relentless advocacy, we acknowledged a landmark $32.5 billion settlement against tobacco companies — an important step in acknowledging decades of harm. But now, the real work begins.

Lung health has never been more urgent. Would you consider a gift that will help us protect it?

Stay Healthy This Flu Season: Symptoms, Treatment, and Prevention

Influenza, commonly known as the flu, is a contagious viral infection that affects the nose, throat, and lungs. It is caused by influenza A and B viruses and spreads easily, especially during the late fall and winter months. In Canada, about 5-10% of adults and 20-30% of children get infected each year. 

Pfizer Canada and partners announce quality improvement grant recipients for Canada’s most prevalent cancers

This World Cancer Day, Pfizer Canada ULC, together with Rethink Breast Cancer, Colorectal Cancer Canada, Lung Health Foundation, Lung Cancer Canada, and the Quebec Lung Association, is pleased to announce the 2024 recipients of a series of grants to help advance oncology care and innovation in Canada. The competitive grants are awarded for proposals that aim to improve the quality of cancer care for Canadians living with metastatic cancer such as non-small cell lung cancer, colorectal cancer, prostate cancer or breast cancer.